A pivotal Phase 3 registration trial evaluating RYBREVANT-based regimens as second-line treatment in colorectal cancer
Latest Information Update: 17 Sep 2024
At a glance
- Drugs Amivantamab (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Johnson & Johnson
- 17 Sep 2024 New trial record
- 14 Sep 2024 According to a Johnson & Johnson media release, pivotal Phase 3 registration trials evaluating RYBREVANT-based regimens as first- and second-line treatment in colorectal cancer are planned.